mˈoʊst ˌɪndᵻvˈɪdʒuːəlz wɪð ˌɛsbˈiːkˈæd ɑːɹ aɪdˈɛntᵻfˌaɪd θɹuː nˈuːbɔːɹn skɹˈiːnɪŋ, wˌɛɹ ðeɪ pɹɪzˈɛnt wɪð ɐn ˌɛlɪvˈeɪʃən əvə fˈaɪv kˈɑːɹbən ɐkˈɪlkɑːɹnˌɪtiːn spˈiːsiːz.
Most individuals with SBCADD are identified through newborn screening, where they present with an elevation of a five carbon acylcarnitine species.